相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value
Peter Arlett et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA
Irene Canales Ruiz et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)
Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
Varsha Gupta et al.
JOURNAL OF HEMATOLOGY (2022)
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
Grzegorz S. Nowakowski et al.
CLINICAL CANCER RESEARCH (2022)
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Mehdi Hamadani et al.
BLOOD (2021)
Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Grzegorz S. Nowakowski et al.
BLOOD (2021)
Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study
Geoffrey Shouse et al.
BLOOD (2021)
Implementing Historical Controls in Oncology Trials
Olivier Collignon et al.
ONCOLOGIST (2021)
Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1
Gilles Salles et al.
ADVANCES IN THERAPY (2021)
Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
Anna Nydegger et al.
CANCERS (2021)
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation
Clarisse Cazelles et al.
LEUKEMIA & LYMPHOMA (2021)
Diffuse large B-cell lymphoma: new targets and novel therapies
Bruce D. Cheson et al.
BLOOD CANCER JOURNAL (2021)
CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration
Linda Kwakkenbos et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell et al.
HAEMATOLOGICA (2021)
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
David G. Maloney et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Single-arm oncology trials and the nature of external controls arms
Mustafa Hashmi et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) versus salvage chemotherapy in refractory large B-cell lymphoma
Sattva S. Neelapu et al.
Blood Advances (2021)
Shorter Diagnosis-to-Treatment Interval in Diffuse Large B-Cell Lymphoma is Associated With Inferior Overall Survival in a Large, Population-Based Registry
Danielle N. Blunt et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
E. Gonzalez-Barca et al.
BONE MARROW TRANSPLANTATION (2020)
The Advantages and Challenges of Using Real-World Data for Patient Care
Yunn-Fang Ho et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
Alessandro Rambaldi et al.
CANCER (2020)
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment
Jeffrey A. Cohen et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Identification of Early Predictive Markers of Toxicity and Efficacy in Patients with DLBCL Treated with Axicabtagene Ciloleucel
Rawan Faramand et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Trial designs using real-world data: The changing landscape of the regulatory approval process
Elodie Baumfeld Andre et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Jie Zhang et al.
ADVANCES IN THERAPY (2020)
Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma
Olalekan O. Oluwole et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda et al.
Lancet Haematology (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles et al.
LANCET ONCOLOGY (2020)
Letter to the Editor Regarding Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma
Jie Zhang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Reporting of Multi-Arm Parallel-Group Randomized Trials Extension of the CONSORT 2010 Statement
Edmund Juszczak et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Impact of missing data on bias and precision when estimating change in patient-reported outcomes from a clinical registry
Olawale F. Ayilara et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2019)
A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
Sattva S. Neelapu et al.
BLOOD (2019)
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Jake R. Schade et al.
BLOOD (2019)
Big Data in Cancer Research: Real-World Resources for Precision Oncology to Improve Cancer Care Delivery
Chiaojung Jillian Tsai et al.
SEMINARS IN RADIATION ONCOLOGY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A simplified guide to randomized controlled trials
Amar Bhide et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2018)
Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
E. Van den Neste et al.
BONE MARROW TRANSPLANTATION (2017)
Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement
Kala Visvanathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Real-world Data for Clinical Evidence Generation in Oncology
Sean Khozin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Real-world Data for Clinical Evidence Generation in Oncology
Sean Khozin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Jessica M. Franklin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma
Steven I. Park et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Distinguishing Selection Bias and Confounding Bias in Comparative Effectiveness Research
Sebastien Haneuse
MEDICAL CARE (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma
Tarec Christoffer El-Galaly et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs: Update, July 2010 to June 2014
Frank J. Sasinowski et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2015)
Potential and Challenges of Patient-Generated Health Data for High-Quality Cancer Care
Arlene E. Chung et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide Retrospective Study
Dai Chihara et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Metrics for covariate balance in cohort studies of causal effects
Jessica M. Franklin et al.
STATISTICS IN MEDICINE (2014)
Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
Sarah J. Nagle et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial
Nicolas Mounier et al.
HAEMATOLOGICA (2013)
Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ken Ohmachi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Optimal Caliper Width for Propensity Score Matching of Three Treatment Groups: A Monte Carlo Study
Yongji Wang et al.
PLOS ONE (2013)
Estimating Propensity Scores and Causal Survival Functions Using Prevalent Survival Data
Yu-Jen Cheng et al.
BIOMETRICS (2012)
Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
James E. Signorovitch et al.
VALUE IN HEALTH (2012)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
Peter C. Austin
PHARMACEUTICAL STATISTICS (2011)
Registries in systemic sclerosis: a worldwide experience
Felice Galluccio et al.
RHEUMATOLOGY (2011)
Survivor treatment bias, treatment selection bias, and propensity scores in observational research
Peter C. Austin et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma
Luis F. Porrata et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Beyond randomized controlled trials: A critical comparison of trials with nonrandomized studies
Henrik Toft Sorensen et al.
HEPATOLOGY (2006)
Too much ado about propensity score models? Comparing methods of propensity score matching
Onur Baser
VALUE IN HEALTH (2006)
A comparison of propensity score methods: A case-study estimating the effectiveness of post-AMI statin use
PC Austin et al.
STATISTICS IN MEDICINE (2006)
Indications for propensity scores and review of their use in pharmacoepidemiology
RJ Glynn et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
A review of uses of health care utilization databases for epidemiologic research on therapeutics
S Schneeweiss et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Practical clinical trials - Increasing the value of clinical research for decision making in clinical and health policy
SR Tunis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma
PA Hamlin et al.
BLOOD (2003)
分享论文
